Lighthouse Financial LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) during the third quarter, HoldingsChannel.com reports. The firm bought 2,012 shares of the medical research company’s stock, valued at approximately $832,000.
Several other institutional investors also recently modified their holdings of NTRA. BlackRock Inc. bought a new stake in shares of Natera in the 2nd quarter valued at about $2,962,770,000. Arrowstreet Capital Limited Partnership boosted its stake in Natera by 1.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock worth $238,334,000 after acquiring an additional 11,793 shares during the last quarter. Maverick Capital Ltd. grew its holdings in Natera by 24.1% during the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after purchasing an additional 227,605 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Natera by 10.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after purchasing an additional 80,440 shares during the period. Finally, Bank of America Corp DE acquired a new position in Natera during the second quarter valued at approximately $199,960,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.
Natera Trading Up 0.6%
NTRA opened at $403.95 on Friday. The stock has a market capitalization of $58.23 billion, a P/E ratio of -297.02 and a beta of 1.50. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The firm’s fifty day simple moving average is $367.33 and its 200 day simple moving average is $282.37.
Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same quarter in the prior year, the company earned ($0.74) EPS. The company’s revenue was up 37.7% on a year-over-year basis. On average, equities research analysts predict that Natera, Inc. will post -1.02 EPS for the current fiscal year.
Insider Transactions at Natera
In related news, CEO Steven Chapman sold 3,580 shares of Natera stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total value of $909,570.60. Following the sale, the chief executive officer owned 102,973 shares of the company’s stock, valued at approximately $26,162,350.11. This trade represents a 3.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 6,517 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the completion of the sale, the insider owned 197,257 shares in the company, valued at $63,424,043.21. The trade was a 3.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 52,985 shares of company stock valued at $16,119,137 over the last three months. 5.05% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Several equities research analysts have commented on NTRA shares. Roth Capital began coverage on shares of Natera in a research note on Thursday. They issued a “buy” rating and a $475.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Natera from $360.00 to $460.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Canaccord Genuity Group upped their price objective on shares of Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Guggenheim lifted their target price on Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, TD Cowen lifted their target price on Natera from $340.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average target price of $379.20.
View Our Latest Stock Report on Natera
Natera Company Profile
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.
In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.
Read More
- Five stocks we like better than Natera
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
- Chefs’ Warehouse Has Rallied 76%—Can the Stock Keep Climbing?
- MarketBeat Week in Review – 10/19 – 10/23
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
